NYRADA INC (ASX:NYR) 6 Protecting Innovation, Expanding Opportunity Innovation must be protected to thrive. In September 2024, we submitted ‘Composition of Matter’ patent applications across key global jurisdictions, including Australia, Europe, and North America. These patents, once granted, will secure exclusivity over our TRPC assets for at least 20 years, reinforcing our leadership in this emerging field. Beyond our lead cardioprotection indication, we are also actively exploring the broader therapeutic potential of TRPC inhibition. Scientific literature suggests applications in autoimmune, pulmonary, and oncological diseases. While our current focus remains on cardioprotection and neuroprotection, the horizon is wide, and we are well-positioned to expand our pipeline. The Right Team to Develop Xolatryp Our CEO, James Bonnar, has assembled a talented team of scientists, drawing on his unique combined background as a chemist and his extensive experience in clinical operations. We are also guided by a worldclass Scientific Advisory Board, chaired by Professor Gary Housley. In addition, our Board of Directors brings a wealth of experience and strategic connections that will be invaluable in supporting James's efforts to secure development partners for Xolatryp across what we anticipate will be multiple high-impact indications. A Platform for Global Impact Australia continues to offer a world-class environment for drug development, with a robust R&D rebate system and a deep pool of scientific talent. Our collaboration with the U.S. military remains a cornerstone of our strategy, offering both validation and a potential pathway to market and the scale of the opportunities before us are immense. Looking Forward As we look to the future, our priorities are clear: initiate Phase II efficacy studies and continue to build a pipeline of TRPC-targeted therapies. We are not just developing a drug—we are building a platform, a team, and a vision for a healthier tomorrow. I extend my heartfelt thanks to my fellow Non-Executive Directors for their guidance, to our CEO James Bonnar for his leadership, and to the entire Nyrada team for their dedication and ingenuity. To our CDI holders, thank you for your continued support and belief in our mission. Together, we are not just navigating the future, we are shaping it. With science as our compass and purpose as our sail, we move forward with confidence, courage, and conviction. Adventure awaits! Warm regards, John Moore Non-Executive Chair “Nyrada’s advancement of Xolatryp from Phase I to Phase IIa marks a key value inflection point, positioning the company to create significant economic and therapeutic value.”
RkJQdWJsaXNoZXIy MjE2NDg3